DC Chemicals
-Chemicals for Life Science
-competitive price and high quality!www.dcchemicals.com
COA of UAMC1110-NH2
Description:
UAMC1110-NH2 is a derivative of UAMC1110 (SP-13786) with an aminobutoxy group, making it a useful intermediate for synthesizing UAMC1110 conjugates. UAMC1110 is a potent and selective FAP inhibitor with low nanomolar potency and high specificity over related proteases. Together, UAMC1110-NH2 and UAMC1110 have significant potential for advancing FAP-targeted therapies, imaging agents, and research tools, particularly in cancer and fibrotic diseases.
Chemical Information
| Catalog | Featured products |
|---|---|
| Purity of current batch | >98% |
| CAS | 2758337-19-6 |
| Molecular Weight (MW) | 431.4438 |
| Molecular Formula | C21H23F2N5O3 |
| Storage | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
Handling:
Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months.
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Reference:
1: De Decker A, Vliegen G, Van Rompaey D, Peeraer A, Bracke A, Verckist L, Jansen K, Geiss-Friedlander R, Augustyns K, De Winter H, De Meester I, Lambeir AM, Van der Veken P. Novel Small Molecule-Derived, Highly Selective Substrates for Fibroblast Activation Protein (FAP). ACS Med Chem Lett. 2019 Jul 9;10(8):1173-1179. doi: 10.1021/acsmedchemlett.9b00191. PMID: 31413802; PMCID: PMC6691567.
2: Moon ES, Elvas F, Vliegen G, De Lombaerde S, Vangestel C, De Bruycker S, Bracke A, Eppard E, Greifenstein L, Klasen B, Kramer V, Staelens S, De Meester I, Van der Veken P, Rösch F. Targeting fibroblast activation protein (FAP): next generation PET radiotracers using squaramide coupled bifunctional DOTA and DATA5m chelators. EJNMMI Radiopharm Chem. 2020 Jul 29;5(1):19. doi: 10.1186/s41181-020-00102-z. PMID: 32728930; PMCID: PMC7391456.
3: Gunderson AJ, Yamazaki T, McCarty K, Phillips M, Alice A, Bambina S, Zebertavage L, Friedman D, Cottam B, Newell P, Gough MJ, Crittenden MR, Van der Veken P, Young KH. Blockade of fibroblast activation protein in combination with radiation treatment in murine models of pancreatic adenocarcinoma. PLoS One. 2019 Feb 6;14(2):e0211117. doi: 10.1371/journal.pone.0211117. PMID: 30726287; PMCID: PMC6364920.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7391456/